BCL2 and acute myeloid leukemia: A combination regimen of VEN/AZA, consisting of venetoclax (VEN), which blocks anti-apoptotic B cell lymphoma-2 (Bcl-2) protein, and azacytidine (AZA), which inhibits DNA methyltransferase, has become a standard of care (SoC) for treatment of elderly patient AML.